Darifenacin
From Wikipedia, the free encyclopedia
 |
|
|
Darifenacin
|
|
| Systematic (IUPAC) name | |
| 2-[1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl] pyrrolidin-3-yl] -2,2-diphenyl-acetamide | |
| Identifiers | |
| CAS number | 133099-04-4 |
| ATC code | G04BD10 |
| PubChem | 444031 |
| DrugBank | APRD00903 |
| Chemical data | |
| Formula | C28H30N2O2 |
| Mol. weight | 426.55 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 15 to 19% (dose-dependent) |
| Protein binding | 98% |
| Metabolism | Hepatic (CYP2D6- and CYP3A4-mediated) |
| Half life | 13 to 19 hours |
| Excretion | Renal (60%) and biliary (40%) |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status |
℞-only(US) |
| Routes | Oral |
Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence.
Darifenacin works by blocking the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. It thereby decreases the urgency to urinate. It should not be used in people with urinary retention.
[edit] Administration
Darifenacin is administered as a once-daily extended-release oral tablet.
[edit] Side effects
- Blurred vision
- Decreased sweating, possibly leading to heat prostration
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
| Urologicals (G04) edit | ||
|---|---|---|
| Acidifiers: | ||
| Urinary antispasmodics: |
Darifenacin, Emepronium, Flavoxate, Meladrazine, Oxybutynin, Propiverine, Solifenacin, Terodiline, Tolterodine, Trospium |
|
| For erectile dysfunction: |
Alprostadil, Apomorphine, Moxisylyte, Papaverine, Phentolamine, Sildenafil, Tadalafil, Vardenafil, Yohimbine |
|
| Other urologicals: |
Acetohydroxamic acid, Collagen, Dimethyl sulfoxide, Magnesium hydroxide, Phenazopyridine, Phenyl salicylate, Succinimide |
|
| For benign prostatic hypertrophy: |
5α-reductase inhibitors: Dutasteride, Finasteride |
|
